Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

660 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD) from all causes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

NCT00098384

Diarrhea

COMPLETED PHASE2

Rifaximin for Prevention of Travellers' Diarrhea

NCT00742469

Diarrhea

COMPLETED PHASE3

Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea

NCT00292344

Travelers' Diarrhea

COMPLETED PHASE4

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT02498301

Travelers' Diarrhea Functional Bowel Disorders Reactive Arthritis

COMPLETED NA

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

NCT02498418

Diarrhea

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Travelers' diarrhea (TD) is the most common illness in travelers to the developing world, occurring in 60% or more of international travelers to high-risk areas. It can be quite debilitating for the usual 2 to 4 days of the illness and may lead to disruption of travel plans. Findings from recent studies have indicated that the chronic post-travel illness may prove to be of greater clinical and public health significance than the acute illness. Specifically, persistent diarrhea has been reported in 2% to 10% of travelers developing diarrhea. Moreover, bacterial enterocolitis, including that associated with TD, leads to post-infectious irritable bowel syndrome in 4% to 31% of patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diarrhea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rifaximin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is in good health (as determined by medical history)
2. Subject is planning on traveling anywhere outside the US (except Canada) for at least 5 and no more than 14 days
3. Subject is scheduled to depart on their planned trip no later than 14 days and no earlier than 4 days after having blood drawn for clinical laboratory assessments and urine collected for a pregnancy test (females of childbearing potential only)

Exclusion Criteria

1. Subject has hypersensitivity or allergy to rifaximin or rifampin
2. Subject has known or suspected alcohol abuse or illicit drug use within 1 year of enrollment
3. Subject participated in an investigational drug or device study within the 30 days prior to enrollment
4. Subject received rifaximin in a previous clinical study
5. Subject received any systemic or gastrointestinal-specific antibiotic within 7 days of the first dose of study drug
6. Subject received antidiarrheal medication (eg, loperamide, lactobacillus, BSS, Kaopectate®) within 24 hours of the first dose of study drug

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes